Vivity Outcomes in Patients With Early Stage Glaucoma (VIVA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Keeley Puls
- Phone Number: 402 740 9420
- Email: Keeley.puls@vancethompsonvision.com
Study Locations
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57108
- Vance Thompson Vision
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients at least age 45 years of age undergoing uncomplicated cataract surgery with optional concomitant minimally invasive glaucoma surgery (MIGS)
- Subjects with documented diagnosis of pre-perimetric glaucoma
- Calculated lens power within Vivity/Vivity toric range
- Willing and able to comprehend informed consent and complete 4-6 month post-op visit
- Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion
Exclusion Criteria:
- Ocular comorbidity, other than pre-perimetric glaucoma, that could reduce the potential postoperative BCDVA
- Previous ocular surgery including refractive surgery
- Subjects who are pregnant or plan to become pregnant during the course of the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Vivity
Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.
|
Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Uncorrected Distance Visual Acuity
Time Frame: 4-6 months
|
4-6 months
|
|
Uncorrected Intermediate Visual Acuity
Time Frame: 4-6 months
|
4-6 months
|
|
Uncorrected Near Visual Acuity
Time Frame: 4-6 months
|
4-6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Contrast Sensitivity
Time Frame: 4-6 months
|
As measured by Pelli Robson Chart
|
4-6 months
|
|
Patient Satisfaction and Spectacle Independence Survey Results
Time Frame: 4-6 months
|
4-6 months
|
|
|
Mean Refractive Spherical Equivalent
Time Frame: 4-6 months
|
4-6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brian M Shafer, MD, Vance Thompson Vision
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VIVA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.